61
Participants
Start Date
February 28, 2009
Primary Completion Date
December 31, 2014
Study Completion Date
February 28, 2015
NK012
30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
Sarah Cannon Research Institute, Nashville
Lead Sponsor
Nippon Kayaku Co., Ltd.
INDUSTRY